Negative effect of vitamin D on kidney function: a Mendelian randomization study by ,
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative effect of vitamin D on kidney function: a Mendelian
randomization study
Citation for published version:
CKDGen Consortium 2018, 'Negative effect of vitamin D on kidney function: a Mendelian randomization
study', Nephrology dialysis transplantation. https://doi.org/10.1093/ndt/gfy074
Digital Object Identifier (DOI):
10.1093/ndt/gfy074
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nephrology dialysis transplantation
Publisher Rights Statement:
This is the author’s peer-reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
 1 
Mendelian randomization study supports a negative causal 
effect of vitamin D on kidney function  
 
Alexander Teumer1,2, Giovanni Gambaro3, Tanguy Corre4,5, Murielle Bochud4, Peter 
Vollenweider6, Idris Guessous7, Marcus E. Kleber8, Graciela E. Delgado8, Stefan Pilz9, Winfried 
März10,11, Catriona LK Barnes12, Peter K. Joshi12, James F. Wilson12,13, Martin H. de Borst14, 
Gerjan Navis14, Pim van der Harst15, Hiddo J. Lambers Heerspink16, Georg Homuth17, Karlhans 
Endlich18, Matthias Nauck2,19, CKDGen Consortium, Anna Köttgen20,21, Cristian Pattaro22, 
Pietro Manuel Ferraro3 
 
 
1 Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, 
Germany 
2 DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald, 
Germany 
3 Divisione di Nefrologia, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica 
del Sacro Cuore, Rome, Italy 
4 Institute of Social and Preventive Medicine, Route de la Corniche 10,1010 Lausanne, 
Switzerland 
5 Department of computational biology, University of Lausanne, Lausanne, Switzerland 
6 CHUV, Internal Medicine, BH,1011 Lausanne, Switzerland 
7 Division of Primary Care Medicine, University Hospital of Geneva, Geneva,  Switzerland 
8 Vth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Diabetology, 
Rheumatology), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 
68167 Mannheim, Germany 
9 Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical 
University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria 
10 Synlab Academy, Synlab Holding Deutschland GmbH, P5,7, 68161 Mannheim, Germany 
11 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University 
Graz, Auenbruggerplatz 15, 8036 Graz, Austria 
12 Centre for Global Health Research, Usher Institute for Population Health Sciences and 
Informatics, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, Scotland 
13 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of 
Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, Scotland 
14 Department of Internal Medicine, Division of Nephrology, PO Box 30.001, 9700 RB 
Groningen, The Netherlands 
15 Department of Cardiology, PO Box 30.001, 9700 RB Groningen, The Netherlands 
16 Department of Clinical Pharmacy and Pharmacology, PO Box 30.001, 9700 RB Groningen, 
The Netherlands 
17 Interfaculty Institute for Genetics and Functional Genomics, University Medicine 
Greifswald, 17475 Greifswald, Germany 
18 Institute of Anatomy and Cell Biology, University Medicine Greifswald, 17475 Greifswald, 
Germany 
19 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, 
17475 Greifswald, Germany 
 2 
20 Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of 
Freiburg, Hugstetter Str. 49, 79106 Freiburg, Germany 
21 Dept. of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 625 N Wolfe St., 
Baltimore, MD 21205, USA 
22 Institute for Biomedicine, Eurac Research, Galvanistraße/Via Galvani 31, 39100 
Bozen/Bolzano, Italy 
 
 
 
 
Correspondence: 
 
Pietro Manuel Ferraro, MD, MSc, PhD 
Università Cattolica del Sacro Cuore 
Divisione di Nefrologia, Fondazione Policlinico Universitario A. Gemelli 
00168 Rome 
Italy 
Tel: +39-3015-9776 
pietromanuel.ferraro@unicatt.it 
 
Alexander Teumer, PhD 
University Medicine Greifswald 
Walther-Rathenau-Str. 48 
17475 Greifswald 
Germany 
Tel: +49 (0)3834-8619579 
ateumer@uni-greifswald.de 
 
  
 3 
Abstract 
Background: The kidney plays a central role in the regulation of vitamin D metabolism. It is 
not clear, however, whether vitamin D influences kidney function. Previous studies have 
reported conflicting results, which may have been influenced by reverse causation and 
residual confounding. We conducted a Mendelian randomization (MR) study to obtain 
unconfounded estimates of the association between genetically instrumented vitamin D 
metabolites and estimated glomerular filtration rate (eGFR) as well as the urinary albumin-
to-creatinine ratio (UACR). 
Methods: We performed a two-sample MR study based on three single nucleotide variants 
associated with 25(OH)D levels: rs2282679, rs10741657, and rs12785878, related to the 
genes GC, CYP2R1, and DHCR7, respectively. Estimates of the allele-dependent effects on 
serum 25(OH)D and eGFR/UACR were obtained from summary statistics of published 
genome-wide association meta-analyses. Additionally, we performed a one-sample MR 
analysis for both 25(OH)D and 1,25(OH)2D using individual-level data from six cohorts. 
Results: The combined MR estimate supported a negative causal effect of log-transformed 
25(OH)D on log-transformed eGFR (beta −0.013, p = 0.003). The analysis of individual-level 
data confirmed the main findings, and also revealed a significant association of 1,25(OH)2D 
on eGFR (beta = −0.094, p = 0.008). These results show that a 10% increase in serum 
25(OH)D levels cause a 0.3% decrease in eGFR. There was no effect of 25(OH)D on UACR 
(beta 0.032, p = 0.265). 
Conclusion: Our study suggests that circulating vitamin D metabolite levels are negatively 
associated with eGFR. Further studies are needed to elucidate the underlying mechanisms. 
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Introduction 
The kidneys play a central role in the regulation of vitamin D metabolism. They produce the 
25-hydroxyvitamin D3-1α-hydroxylase enzyme that converts 25-hydroxyvitamin D3 
(25[OH]D) to the active form 1α,25-dihydroxyvitamin D3 (1,25[OH]2D). As a consequence, 
during progression of chronic kidney disease (CKD), circulating levels of 1,25(OH)2D decline 
(1). Conversely, whether vitamin D status might affect kidney function, is less clear. Because 
of the aforementioned interrelation between renal function and vitamin D metabolism, 
cross-sectional designs are not appropriate to address this question, because they do not 
allow for reconstructing a temporal relationship between changes of vitamin D status and 
subsequent kidney function alterations. To date, several observational studies investigated 
the effects of vitamin D status on renal function with inconsistent results, with some 
suggesting a beneficial effect (2,3) while others reporting no association or mixed results(4–
6), and even others suggesting a harmful effect(7). In all these studies, decline of kidney 
function was assessed from baseline to follow-up, whereas vitamin D status was measured 
at baseline only. As no information on vitamin D metabolites was available over time, the 
possibility that the findings might reflect reverse causation cannot be ruled out. 
Furthermore, due to the observational nature of these studies, the associations between 
vitamin D and renal function might be influenced by confounding e.g. from inflammation, 
diabetes mellitus, hypertension, or body mass index(8). The Mendelian randomization (MR) 
approach analyzes the relationship between exposure and outcome by an unconfounded 
genetic instrument. It might therefore be useful to overcome the limitations of observational 
studies(9,10) and thus help to disentangle the relationship between vitamin 25(OH)D and 
markers of kidney function. In the present study, we investigated the relationship between 
the levels of circulating 25(OH)D and two measures of kidney function, namely the estimated 
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glomerular filtration rate (eGFR) and the urinary albumin to creatinine ratio (UACR), with a 
MR approach using data from published literature. To further explore the association, we 
additionally analyzed individual-level data from six population-based studies and extended 
the MR analyses to assess a causal effect of 1,25(OH)2D levels on eGFR. Because no genome-
wide association study (GWAS) on 1,25(OH)2D levels was available, we generated and 
analyzed individual level data to close this gap and carry out a MR analysis for 1,25(OH)2D. 
Materials and Methods 
Phenotypes and instrumental variables 
In the initial two-sample MR, we included published genetic association summary statistics 
data on 25(OH)D(11), serum creatinine based eGFR(12), and urinary albumin-to-creatinine 
ratio (UACR)(13) based on n=33,868, 133,720, and 54,448 individuals, respectively. The one-
sample two-stage least-squares MR of 25(OH)D and vitamin 1,25(OH)2D on eGFR was 
calculated using data of 16,442 subjects from six studies (COLAUS, LURIC, ORCADES, 
PREVEND, SHIP and SHIP-Trend) and 5,123 subjects from two studies (LURIC and PREVEND), 
respectively. None of the studies was included in the published 25(OH)D GWAS meta-
analysis (Table 1, Supplemental Material). Additional 2,696 samples of the PREVEND study 
without available genetic information but with measured levels of 25(OH)D and vitamin 
1,25(OH)2D were included in the non-instrumented stratified analyses. All individuals 
analyzed in this project were of European ancestry. 
As an initial selection of the instruments, we considered single nucleotide polymorphisms 
(SNPs) strongly associated with 25(OH)D levels as reported by Wang et al.(11) and Ahn et 
al.(14). Given the different covariate adjustments and the smaller sample size of Ahn et al. 
compared to Wang et al., we focused on the association results of the latter study only: the 
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exonic SNP rs4588 and rs2282679 in GC, rs12785878 in NADSYN1, rs10741657 upstream 
CYP2R1, and rs6013897 downstream CYP24A1. The beta values from the published GWAS 
meta-analyses on eGFR(12) and UACR(13) were used as effect estimates of the SNPs on 
kidney function. As the SNP rs4588, which was also in strong linkage disequilibrium (LD) with 
rs2282679, was not included in these two meta-analyses, it was excluded from subsequent 
analyses.  
All loci significantly associated with 25(OH)D in the study of Wang et al. were evaluated 
whether they represented valid instruments for MR studies (15), taking into account both 
biological and statistical criteria. That is, SNPs were evaluated for a strong association with 
25(OH)D and for potential pleiotropy (association with confounders of the association of 
vitamin D with kidney function to ensure that the SNPs were only associated with kidney 
function through 25(OH)D)(16). Briefly, the SNP rs2282679 is located in an intron of GC 
which encodes a vitamin D binding protein that transports vitamin D metabolites in the 
blood. The intronic SNP rs12785878 of NADSYN1 has several SNPs in high LD located in or 
near the 7-dehydrocholesterol reductase encoding gene DHCR7. This product of this gene as 
well as the cytochrome P450 family 2 subfamily R member 1 encoded by CYP2R1 is involved 
in vitamin D synthesis. However, we observed a significant association of rs6013897 with 
eGFR (p = 7.5x10−10). This SNP is located in close vicinity of CYP24A1 which encodes an 
enzyme deactivating vitamin 1,25(OH)2D(17,18) in the kidney as well as other tissues, and 
thus we cannot exclude that the SNP affects kidney function via other mechanisms than 
exclusively through 25(OH)D levels. Therefore, this SNP could not be considered as a valid 
instrument for the analysis of kidney function as an outcome and was excluded from the MR 
analyses. The F-statistics of the remaining three SNPs rs2282679, rs10741657 and 
rs12785878 were higher than the recommended value of ten(10) according to the ~6000 
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individuals included in Berry et al. supporting these SNPs as strong instruments for both our 
two- and one-sample MR studies (Figures 1 and 2). 
Because in Wang et al. no effect estimates were available because the GWAS were pooled 
using a z-score based meta-analysis, effect estimates required for the MR as well as their 
standard errors were estimated using the provided allele frequency, effect direction, p-
value, and sample size as described previously(19). The phenotypic variance was set to one 
whereas the effect estimates represent the change of one standard deviation unit of the log-
transformed and covariate-adjusted 25(OH)D values. We used the 3,159 SHIP-1 samples with 
available SNP information and 25(OH)D values to test the method and compare the 
estimated effect sizes with the calculated ones (Supplementary Table 1). 
Statistical analyses 
For the analyses, all traits were transformed using the natural logarithm. The effect sizes of 
the 25(OH)D traits correspond to one standard deviation unit of the log-transformed values 
adjusted for sex, age and body mass index, as well as season (log[25(OH)D])(11). The effect 
sizes of the kidney function traits correspond to a unit change of log-transformed eGFR (4-
parameter MDRD equation using calibrated creatinine measurements, log[eGFR]) and UACR 
values, respectively(12,13).  
The causal effect estimates of serum 25(OH)D on kidney function, based on the published 
GWAS meta-analysis results, were calculated using an inverse-variance meta-analysis of the 
two-sample MR triangulation per SNP (20), with its estimated effect sizes on 25(OH)D, and 
the effect sizes and their standard errors of the corresponding kidney trait as input. 
MR based on individual study data of 25(OH)D and vitamin 1,25(OH)2D on eGFR was 
calculated using a one-sample two-stage least-squares analysis. The standardized residuals 
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of the log-transformed vitamin D traits adjusted for the same covariates as in the GWAS of 
Wang et al. (i.e. sex, age, body mass index, season) were used as exposure (log[25(OH)D] and 
log[1,25(OH)2D], respectively). The log(eGFR) was used as outcome. In each study, linearity 
of the relationship between log(25(OH)D) and log(eGFR) was assessed via locally-weighted 
polynomial regression, as implemented in the R-package lowess. The standard deviation of 
log(25[OH]D) that was needed to transform the effect estimates of the standardized 
residuals back to the original log-scale for calculating the relative change of the causal effects 
was estimated in the SHIP cohort (σ=0.44). 
Simple (non-instrumented) association analyses were performed by fitting linear regression 
models of log(eGFR) values on log(25(OH)D) (n=19,138) and log(1,25[OH]2D) (n=7,819), 
respectively, using the same cohorts and adjustments for covariates included in the one-
sample MR (Table 1, Supplemental Material). Stratified analyses were performed according 
to the chronic kidney disease (CKD) status, defined as eGFR <60 ml/min/1.73m². 
All analyses were performed using the R software package(21). Individual data analyses were 
performed in each cohort separately by distributing a centralized script and meta-analyzing 
the results afterwards by inverse-variance weighting. Significance of the statistical tests was 
set at α= 0.025, corresponding to a level of 0.05 divided by the two outcomes tested (eGFR 
and UACR). 
Results 
The two-sample MR analysis for kidney function supported a negative causal effect of 
25(OH)D levels on eGFR (beta = −0.013, p = 0.003, Figure 1, Supplementary Figure 1A) with 
relatively low heterogeneity between the three instruments (I²=28%). This result was 
reinforced by the one-sample MR analysis: beta = −0.033, p = 0.013, Supplementary Figure 
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2A, Supplementary Table 2). Additionally, a one-sample MR showed a significant association 
of vitamin 1,25(OH)2D on eGFR (beta = −0.094, p = 0.008, Supplementary Figure 2B, 
Supplementary Table 2). No indication of a non-linear relation between these traits was 
observed (Supplementary Figures 4 and 5). There was no evidence of a causal association 
between Vitamin D and UACR (beta = 0.032, p = 0.265, I²=0%, Figure 2, Supplementary 
Figure 1B) using the association results of published GWAS. 
To investigate possible reasons for the previously reported, conflicting association between 
lower levels of 25(OH)D and impaired kidney function(2,5), we performed a non-
instrumented association between 25(OH)D levels and eGFR stratified by CKD status. We 
observed an negative association between eGFR and 25(OH)D in the 18,029 non-CKD 
individuals (beta = −0.025, p = 1.1x10−66, Supplementary Figure 3E) and a positive association 
in the 1,109 CKD individuals (beta = 0.014, p = 3.1x10−4, Supplementary Figure 3C). In 
contrast, vitamin 1,25(OH)2D was positively associated with eGFR in both the 448 CKD 
subjects (beta = 0.044, p = 5.2x10−13, Supplementary Figure 3D) and in the 7,371 non-CKD 
individuals (beta = 0.006, p = 0.002, Supplementary Figure 3F). Comparing the causal one-
sample MR effects with the observed (non-instrumented) association results of eGFR using 
the same individuals, the effect directions were concordant for 25(OH)D (beta = −0.022, p = 
7.2x10−33, Supplementary Figure 3A) but not for vitamin 1,25(OH)2D (beta = 0.037, p = 
3.0x10−33, Supplementary Figure 3B). 
Based on the estimated causal effects, a 10% increase in serum 25(OH)D levels corresponds 
to a 0.3% decrease in eGFR (two-sample MR). The estimated change in 25(OH)D levels 
depending on the number of trait increasing alleles per instrument varies from 3% to 18% 
(Figure 3), whereas individuals being homozygous for all trait increasing alleles of these three 
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SNPs are estimated to have 37% higher 25(OH)D levels compared to individuals without trait 
increasing alleles. 
Discussion 
Using the largest available GWAS on vitamin D metabolites and eGFR, we observed a 
potentially negative causal relationship between serum 25(OH)D and kidney function 
defined by eGFR. This association could be reinforced by individual study MR analyses. 
Additionally, a similar negative causal association was revealed for vitamin 1,25(OH)2D with 
eGFR.  
Although these results are consistent with the observational association results of 25(OH)D 
and kidney function in the population-based cohorts participating in this study, they 
contradict the previously reported associations of lower vitamin D status with increased risk 
of CKD progression(2,5) assessed as either rapid decline in eGFR or risk of incident end-stage 
renal disease. However, when limiting our observational analyses to individuals with CKD, 
the effect directions were concordant with those reported for CKD progression from 
previous observational studies. A potential explanation for this observation could be an 
impaired re-absorption of vitamin D metabolites in the proximal tubules due to a 
substantially reduced kidney function, resulting in reduced serum vitamin D levels. This 
reverse causation could mask a possible causal effect of higher vitamin D levels on lower 
eGFR. The outcomes analyzed in these two previous studies suggest that individuals with low 
kidney function at baseline are more likely to be included in the group of CKD progressors 
than the individuals with normal kidney function, which in turn could lead to confounding of 
the observed association of vitamin D status with kidney function. Supporting our 
explanation, other population-based longitudinal studies, which either excluded patients 
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with CKD at baseline or did not use a rapid eGFR decline for case definition did not show a 
significant positive association of vitamin D status with change in kidney function(3,4,6,7). 
Even though associations of vitamin D status with change in albuminuria were reported 
previously(3,6,22), no causal effect was shown in our study using two-sample MR analysis. 
Besides the possibility that no true causal effect exists, our MR analyses included only cross-
sectional measurements of UACR to assess albuminuria, it was limited in detecting non-
linear log-log transformed causal associations of 25(OH)D on UACR, and may still have been 
underpowered. Another issue might be the biological variability of UACR as well as the lower 
precision of UACR assessment in healthy individuals compared with eGFR because of limit-
of-detection issues with the urinary albumin assay. The latter issue could affect the effect 
magnitude of genetic association estimates(23). 
As both exposure and outcome were log-transformed prior to the analysis, a non-linear 
causal relation between untransformed 25(OH)D and eGFR is likely. However, the causal 
effect with respect to the relative change on the original scale of the traits is rather small, 
suggesting that other factors not directly related to 25(OH)D levels are clinically more 
important for kidney function. 
Several limitations apply to our study affecting also the significant causal associations of 
vitamin D traits on eGFR. Because LURIC is a hospital-based cohort selected for an acute 
coronary syndrome, a one-time estimate of glomerular filtration rate may not accurately 
represent CKD status. However, the LURIC study was included in previous genetic analyses 
that gave rise to clear and homogeneous signals. The cross-sectional data limits possible 
interpretations of the molecular mechanisms underlying the causality. In particular, it would 
be of interest whether an increase in 25(OH)D levels causes a decline in eGFR or reduced 
25(OH)D levels have a protective effect on kidney function. 
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There are different GFR estimating methods available, including the CKD-EPI equation, which 
may provide more precise estimates in population-based samples compared to the MDRD 
formula(24). However, no large-scale GWAS based on CKD-EPI eGFR was conducted until 
today. For this reason, we used the results of the GWAS of logarithm-transformed cystatin-C-
based eGFR, carried out on 33,152 participants by the CKDGen Consortium(12) to assess the 
robustness of our causal estimates. The causal effect of 25(OH)D on the cystatin-based eGFR 
was of -0.014 (p = 0.11), thus almost identical to that obtained with the MDRD-based 
estimate. The lack of statistical significance is expected given the substantially smaller 
sample size. 
Furthermore, there is no readily available explanation for our finding of a negative 
association between 25(OH)D and eGFR. Circulating levels of 25(OH)D are generally used to 
gauge vitamin D status as they increase dose-dependently following vitamin D 
administration. However, the formation of 1,25(OH)2D is tightly regulated and unlikely to 
increase due to higher levels of 25(OH)D, as shown by randomized controlled trials in which 
supplementation with vitamin D did not consistently cause an increase in 1,25(OH)2D 
levels(25,26). That circulating levels of 25(OH)D might fail to capture the complexity of the 
relationship with kidney function is confirmed by the study by Rebholz et al.(5), in which the 
authors found no association between 25(OH)D and risk of end-stage renal disease, but a 
significant association for vitamin D binding protein. 
Vitamin D is a lipid soluble hormone, whereas only free vitamin D is passing the cell 
membrane (with the exception of megalin mediated vitamin D uptake in the proximal tubule 
of the kidney and the parathyroid gland) and interacts with the vitamin D receptor(27,28). 
Therefore, additional studies using measurements of free vitamin D could help to shed light 
on the biological mechanisms explaining the causal association revealed in our study. 
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Finally, all analyses were performed based on data of European ancestry individuals thus the 
generalization of the findings with respect to other ethnicities needs to be evaluated. 
In conclusion, our results demonstrate that levels of both 25(OH)D and 1,25(OH)2D are 
negatively associated with eGFR. Further studies are warranted to confirm this finding and to 
look at potential mechanisms for this association. 
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Tables 
Table 1: Characteristics of cohorts included in the one-sample MR and non-instrumented analyses 
Study name 
Study 
design 
Imputation 
panel and 
software 
Genotyping 
platform 
Vitamin D 
measurement 
Serum 
creatinine 
measurement 
Sample 
size 
Women 
% 
Age in 
years 
(SD) 
eGFR in 
ml/min/
1.73 m² 
(SD) 
Vitamin 
D in µg/l 
(SD) 
BMI in 
kg/m² 
(SD) 
COLAUS population 
based 
HRC 
(IMPUTEv2) 
Affymetrix 
500k 
LC/MS/MS and 
LC/HRMS (Bruce 
SJ et al. 2013) 
Jaffe kinetic 
compensated 
method 
5406 53.0 53.4 
(10.8) 
89.9 
(19.5) 
48.5 
(22.7) 
25.8 
(4.5) 
LURIC hospital 
based 
1000Gv3 
(IMPUTEv2) 
Affymetrix SNP 
6.0 
125
I RIA, Vitamin 
D, DiaSorin 
Jaffe, 1997-
2000 
3025 29.6 62.9 
(10.4) 
80.2 
(19.7) 
17.3 
(9.8) 
27.5 
(4.0) 
ORCADES population 
based 
1000Gv3 
(IMPUTEv2) 
Illumina 
Hap300, 
Omni1, 
OmniExpress 
liquid 
chromatography
-tandem mass 
spectrometry 
Jaffe 1774 59.2 54.0 
(14.5) 
88.1 
(23.7) 
35.1 
(18.7) 
27.9 
(5.0) 
PREVEND population 
based 
1000Gv3 
(IMPUTEv2) 
Illumina 
HumanCytoSN
P-12 BeadChip 
LC-MS/MS Roche modular 2098 48.4 51.0 
(13.0) 
 
96.1 
(17.1) 
23.5 
(9.2) 
26.1 
(4.3) 
SHIP population 
based 
1000Gv3 
(IMPUTEv2) 
Affymetrix SNP 
6.0 
IDS-iSYS 25-
Hydroxy Vitamin 
D assay 
Jaffe, 2002 3158 51.8 54.5 
(15.2) 
90.3 
(23.4) 
19.4 
(9.5) 
28.0 
(4.9) 
SHIP-Trend population 
based 
1000Gv3 
(IMPUTEv2) 
Illumina Omni 
2.5 
IDS-iSYS 25-
Hydroxy Vitamin 
D assay 
Jaffe, 2008 981 56.2 50.1 
(13.7) 
92.4 
(22.1) 
25.8 
(11.2) 
27.3 
(4.6) 
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Legends to Figures 
Figure 1: Association results of MR analyses with eGFR 
The figure shows the GWAS meta-analysis association results of the instruments (SNPs) with 
log(25[OH]D) and log(eGFR) (solid arrows) used to estimate the causal effect (dashed arrow) 
between 25(OH)D and eGFR through Mendelian randomization (MR). a. , b., c. represent the 
association results of the respective instruments. 
Figure 2: Association results of MR analyses with UACR 
The figure shows the GWAS meta-analysis association results of the instruments (SNPs) with 
log(25[OH]D) and log(UACR) (solid arrows) used to estimate the causal effect (dashed arrow) 
between 25(OH)D and UACR through Mendelian randomization (MR). a. , b., c. represent the 
association results of the respective instruments. 
Figure 3: Change in 25(OH)D depending on the instruments 
The figure illustrates the per cent change of 25(OH)D levels for each SNP used as an 
instrument depending on the number of trait increasing alleles. The three instruments are 
rs10741657 upstream CYP2R1, rs12785878 in NADSYN1, and rs2282679 in GC. 
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